SMURF2 and non-small cell lung carcinoma: Therefore, we suggest that osimertinib decreases Topo IIα levels via promoting GSK3-dependent and FBXW7-mediated proteasomal degradation in coordination with suppression of SMURF2 expression in EGFRm NSCLC cell lines.